DiaMedica Therapeutics Inc. DMAC
$5.60
▲ +3.48% 24H
About
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing innovative therapies for serious vascular diseases driven by restricted blood flow and endothelial dysfunction. Its lead candidate, DM199, is a recombinant form of the human tissue KLK1 protein, designed to enhance blood flow and vascu…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees35
TickerDMAC
Statistics
Market Cap$301.7M
Revenue (TTM)—
Net Income-$32.8M
Net Margin—
EPS—
P/E-8.07
P/S—
P/B6.23
EV/EBITDA-6.43
ROE-86.5%
Dividend Yield—
Price$5.60
Data: Twelve Data · Revenue = mcap / P/S